Anemia of Aging: The Role of Chronic Inflammation and Cancer

Seminars in Hematology

Volumn 45, Issue 4, 2008, Pages 242-249

  Ferrucci, Luigi ^a   Balducci, Lodovico ^b  

^a NATIONAL INSTITUTE ON AGING   (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANEMIC AGENT; ANTINEOPLASTIC AGENT; ERYTHROPOIESIS STIMULATING AGENT; ERYTHROPOIETIN; FERRITIN; HEMOGLOBIN; HEPCIDIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; UNCLASSIFIED DRUG;

AGED; AGING; ANEMIA; ARTICLE; BLOOD TRANSFUSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHRONIC INFLAMMATION; COMORBIDITY; DEATH; DEEP VEIN THROMBOSIS; DEMENTIA; DISABILITY; DISEASE SEVERITY; DRUG SAFETY; ERYTHROPOIETIN DEFICIENCY; FALLING; FATIGUE; FERRITIN BLOOD LEVEL; FRAIL ELDERLY; FUNCTIONAL DISEASE; HEAD AND NECK CANCER; HEMOGLOBIN DETERMINATION; HIGH RISK POPULATION; HUMAN; LUNG NON SMALL CELL CANCER; LYMPHOMA; MULTIPLE ORGAN FAILURE; NEOPLASM; NONHUMAN; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; PROTEIN DEFICIENCY; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTOR; SOLID TUMOR; TUMOR GROWTH; UTERINE CERVIX CANCER;

AGED; ANEMIA; DRUG THERAPY; ERYTHROCYTE TRANSFUSION; ERYTHROPOIETIN; HEMATINICS; HUMANS; INFLAMMATION; NEOPLASMS; RADIOTHERAPY;

EID: 52049094830     PISSN: 00371963     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2008.06.001     Document Type: Article

References (65)

1. Patel K.V., and Guralnik J.M. Epidemiology of Anemia in Older Adults (2008), Cambridge University Press, Cambridge, UK
2. Culleton B.F., Manns B.J., Zhang J., Tonelli M., Klarenbach S., and Hemmelgarn B.R.L. Impact of anemia on hospitalization and mortality in older adults. Blood 107 (2006) 3841-3846
3. Penninx B.W. Anemia and Functional Decline (2007), Springer, New York, NY
4. Atti A.R., Palmer K., Volpato S., Zuliani G., Winblad B., and Fratiglioni L. Anaemia increases the risk of dementia in cognitively intact elderly. Neurobiol Aging 27 (2006) 278-284
5. Penninx B.W., Pluijm S.M., Lips P., Woodman R., Miedema K., Guralnik J.M., et al. Late-life anemia is associated with increased risk of recurrent falls. J Am Geriatr Soc 53 (2005) 2106-2111
6. Go A.S., Yang J., Ackerson L.M., Lepper K., Robbins S., Massie B.M., et al. Hemoglobin level, chronic kidney disease, and the risks of death and hospitalization in adults with chronic heart failure: The Anemia in Chronic Heart Failure: Outcomes and Resource Utilization (ANCHOR) study. Circulation 113 (2006) 2713-2723
7. Wu W.C., Rathore S.S., Wang Y., Radford M.J., and Krumholz H.M. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med 345 (2001) 1230-1236
8. Ania B.J., Suman V.J., Fairbanks V.F., Rademacher D.M., and Melton III L.J. Incidence of anemia in older people: An epidemiologic study in a well defined population. J Am Geriatr Soc 45 (1997) 825-831
9. Guralnik J.M., Eisenstaedt R.S., Ferrucci L., Klein H.G., and Woodman R.C. Prevalence of anemia in persons 65 years and older in the United States: Evidence for a high rate of unexplained anemia. Blood 104 (2004) 2263-2268
10. Ferrucci L., Guralnik J.M., Bandinelli S., Semba R.D., Lauretani F., Corsi A., et al. Unexplained anaemia in older persons is characterised by low erythropoietin and low levels of pro-inflammatory markers. Br J Haematol 136 (2007) 849-855
11. Ferrucci L., Guralnik J.M., Woodman R.C., Bandinelli S., Lauretani F., Corsi A.M., et al. Proinflammatory state and circulating erythropoietin in persons with and without anemia. Am J Med 118 (2005) 1288
12. Smith Jr. R.E., Aapro M.S., Ludwig H., Pinter T., Smakal M., Ciuleanu T.E., et al. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: Results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol 26 (2008) 1040-1050
13. Thomas G., Ali S., Hoebers F.J., Darcy K.M., Rodgers W.H., Patel M., et al. Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol 108 (2008) 317-325
14. FDA receives new data on risks of anemia drugs. FDA News (2008)
15. Overgaard J., Hoff C., and Hansen H.S. Randomized study of the importance of novel erythropoiesis stimulating protein (Aranesp) for the effect of radiotherapy in patients with primary squamous cell carcinoma of the head and neck (HNSCC). The Danish Head and Neck Cancer Group DAHNCA 10 rand. Eur J Cancer suppl 5 (2007) 7 (abstr 6LB)
16. Wright J.R., Ung Y.C., Julian J.A., Pritchard K.I., Whelan T.J., Smith C., et al. Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 25 (2007) 1027-1032
17. Leyland-Jones B., Semiglazov V., Pawlicki M., Pienkowski T., Tjulandin S., Manikhas G., et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: A survival study. J Clin Oncol 23 (2005) 5960-5972
18. Hedenus M., Adriansson M., San Miguel J., Kramer M.R., Juvonen E., Taylor K., et al. Darbepoetin Alfa 20000161 Study Group. Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: A randomized, double-blind, placebo-controlled study. Br J Haematol 122 (2003) 394-403
19. Henke M., Laszig R., Rube C., Schafer U., Hasse K.D., Schilcher B., et al. Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 362 (2003) 1255-1260
20. Walston J., Hadley E.C., Ferrucci L., Guralnik J.M., Newman A.B., Studenski S.A., et al. Research agenda for frailty in older adults: Toward a better understanding of physiology and etiology: summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older Adults. J Am Geriatr Soc 54 (2006) 991-1001
21. Ruggiero C., and Ferrucci L. The endeavor of high maintenance homeostasis: Resting metabolic rate and the legacy of longevity. J Gerontol A Biol Sci Med Sci 61 (2006) 466-471
22. Chaves P.H., Semba R.D., Leng S.X., Woodman R.C., Ferrucci L., Guralnik J.M., and Fried L.P. Impact of anemia and cardiovascular disease on frailty status of community-dwelling older women: The Women's Health and Aging Studies I and II. J Gerontol A Biol Sci Med Sci 60 (2005) 729-735
23. Woodman R., Ferrucci L., and Guralnik J. Anemia in older adults. Curr Opin Hematol 12 (2005) 123-128
24. Chahal H.S., and Drake W.M. The endocrine system and ageing. J Pathol 211 (2007) 173-180
25. Ferrucci L., Maggio M., Bandinelli S., Basaria S., Lauretani F., Ble A., et al. Low testosterone levels and the risk of anemia in older men and women. Arch Intern Med 166 (2006) 1380-1388
26. Fein H.G., and Rivlin R.S. Anemia in thyroid diseases. Med Clin North Am 59 (1975) 1133-1145
27. Ferrucci L., Corsi A., Lauretani F., Bandelli S., Bartali B., Taubb D.D., et al. The origins of age-related proinflammatory state. Blood 105 (2005) 2294-2299
28. Yaffe K., Kanaya A., Lindquist K., Simonsick E.M., Harris T., Shorr R.I., et al. The metabolic syndrome, inflammation, and risk of cognitive decline. JAMA 292 (2004) 2237-2242
29. Cesari M., Penninx B.W., Newman A.B., Kritchevsky S.B., Nicklas B.J., Sutton-Tyrell K., et al. Inflammatory markers and onset of cardiovascular events: Results from the Health ABC study. Circulation 108 (2003) 2317-2322
30. Cesari M., Penninx B.W., and Pahor M. Inflammatory markers and physical performance in older persons: The InCHIANTI study. J Gerontol A Biol Sci Med Sci 59 (2004) 242-248
31. Alley D.E., Crimmins E., Bandeen-Roche K., Guralnik J., and Ferrucci L. Three-year change in inflammatory markers in elderly people and mortality: The Invecchiare in Chianti study. J Am Geriatr Soc 55 (2007) 1801-1807
32. Ferrucci L., Harris T.B., Guralnik J.M., Tracy R.P., Corti M.C., Cohen H.J., et al. Serum IL-6 level and the development of disability in older persons. J Am Geriatr Soc 47 (1999) 639-646
33. Lipschitz D.A. The anemia of chronic disease. J Am Geriatr Soc 38 (1990) 1258-1264
34. van der Putten K., Braam B., Jie K.E., and Gaillard C.A. Mechanisms of disease: Erythropoietin resistance in patients with both heart and kidney failure. Nat Clin Pract Nephrol 4 (2008) 47-57
35. Scharte M., and Fink M.P. Red blood cell physiology in critical illness. Crit Care Med 31 suppl (2003) S651-S657
36. Eisenstaedt R., Penninx B.W., and Woodman R.C. Anemia in the elderly: Current understanding and emerging concepts. Blood Rev 20 (2006) 213-216
37. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. Blood 102 (2003) 783-788
38. Nemeth E., Rivera S., Gabayan V., Keller C., Pedersen B.K., and Ganz T. IL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidin. J Clin Invest 113 (2004) 1271-1276
39. Lang K.S., Lang P.A., Bauer C., Duranton C., Wider T., Huber S.M., and Lang F. Mechanisms of suicidal erythrocyte death. Cell Physiol Biochem 15 (2005) 195-202
40. Roy C.N., and Andrews N.C. Anemia of inflammation: The hepcidin link. Curr Opin Hematol 12 (2005) 107-111
41. Nemeth E., Valore E.V., Territo M., Schiller G., Lichtenstein A., and Ganz T. Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein. Blood 101 (2003) 2461-2463
42. Denny S.D., Kuchibhatla M.N., and Cohen H.J. Impact of anemia on mortality, cognition, and function in community-dwelling elderly. Am J Med 119 (2006) 327-334
43. Landi F., Russo A., Danese P., Liperoti R., Barillaro C., Bernabei R., and Onder G. Anemia status, hemoglobin concentration, and mortality in nursing home older residents. J Am Med Dir Assoc 8 (2007) 322-327
44. Zakai N.A., Katz R., Hirsch C., Shlipak M.G., Chaves P.H., Newman A.B., et al. A prospective study of anemia status, hemoglobin concentration, and mortality in an elderly cohort: The Cardiovascular Health Study. Arch Intern Med 165 (2005) 2214-2220
45. Balducci L., and Ershler W.B. Cancer and ageing: A nexus at several levels. Nat Rev Cancer 5 (2005) 655-662
46. Benson K., and Balducci L. Anemia and Cancer (2007), Springer, New York, NY
47. Prosnitz R.G., Yao B., Farrell C.L., Clough R., and Brizel D.M. Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer. Int J Radiat Oncol Biol Phys 61 (2005) 1087-1095
48. Grogan M., Thomas G.M., Melamed I., Wong F.L., Pearcey R.G., Joseph P.K., et al. The importance of hemoglobin levels during radiotherapy for carcinoma of the cervix. Cancer 86 (1999) 1528-1536
49. Extermann M., Chen H., Cantor A.B., Corcoran M.B., Meyer J., Grendys E., et al. Predictors of tolerance to chemotherapy in older cancer patients: A prospective pilot study. Eur J Cancer 38 (2002) 1466-1473
50. Schrijvers D., Highley M., De Bruyn E., Van Oosterom A.T., and Vermorken J.B. Role of red blood cells in pharmacokinetics of chemotherapeutic agents. Anticancer Drugs 10 (1999) 147-153
51. Luciani A, Balducci L, Extermann M: Fatigue may be a cause of functional dependence in older cancer patients. Am J Clin Oncol (in press)
52. Tralongo P., Respini D., and Ferrau F. Fatigue and aging. Crit Rev Oncol Hematol 48 suppl (2003) S57-S64
53. Bennett C.L., Silver S.M., Djulbegovic B., Samaras A.T., Blau C.A., Gleason K.J., et al. Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia. JAMA 299 (2008) 914-924
54. Curt G.A., Breitbart W., Cella D., Groopman J.E., Horning S.J., Itri L.M., et al. Impact of cancer-related fatigue on the lives of patients: New findings from the Fatigue Coalition. Oncologist 5 (2000) 353-360
55. Aapro M., Leonard R.C., Barnadas A., Marangolo M., Untch M., Malamos N., et al. Effect of once-weekly epoetin beta on survival in patients with metastatic breast cancer receiving anthracycline- and/or taxane-based chemotherapy: Results of the Breast Cancer-Anemia and the Value of Erythropoietin (BRAVE) study. J Clin Oncol 26 (2008) 592-598
56. Littlewood T.J., Bajetta E., Nortier J.W., Vercammen E., and Rapoport B. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 19 (2001) 2865-2874
57. Vansteenkiste J., Pirker R., Massuti B., Barata F., Font A., Fiegl M., et al. Aranesp 980297 Study Group. Double-blind, placebo-controlled, randomized phase III trial of darbepoetin alfa in lung cancer patients receiving chemotherapy. J Natl Cancer Inst 94 (2002) 1211-1220
58. Auerbach M., Ballard H., Trout J.R., McIlwain M., Ackerman A., Bahrain H., et al. Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy-related anemia: A multicenter, open-label, randomized trial. J Clin Oncol 22 (2004) 1301-1307
59. Nemeth E., and Ganz T. Iron and Aging (2008), Cambridge University Press, Cambridge, UK
60. Bohlius J., Wilson J., Seidenfeld J., Piper M., Schwarner G., Sandercock J., et al. Recombinant human erythropoietins and cancer patients: Updated meta-analysis of 57 studies including 9353 patients. J Natl Cancer Inst 98 (2006) 708-714
61. Henke M., Mattern D., Pepe M., Bezay C., Weissenberger C., Werner M., et al. Do erythropoietin receptors on cancer cells explain unexpected clinical findings?. J Clin Oncol 24 (2006) 4708-4713
62. Crawford J. Erythropoietin: High profile, high scrutiny. J Clin Oncol 25 (2007) 1021-1023
63. Crawford J., Henry D.H., Vansteenkiste J., Ludwig H., Lillie T., Fleishman A., et al. The effect of hemoglobin (hb) level at ESA initiation on outcomes in cancer patients (pts) with chemotherapy-induced anemia (CIA): A patient-based meta-analysis from 6 randomized, placebo-controlled trials (RCTS) of darbepoetin alfa (DA). Blood 110 (2007) 3780
64. Grote T., Yeilding A.L., Castillo R., Butler D., Fishkin E., Henry D.H., et al. Efficacy and safety analysis of epoetin alfa in patients with small-cell lung cancer: A randomized, double-blind, placebo-controlled trial. J Clin Oncol 23 (2005) 9377-9386
65. Rizzo J.D., Somerfield M.R., Hagerty K.L., Seidenfeld J., Bohlius J., Bennett C.L., et al. American Society of Clinical Oncology; American Society of Hematology. Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Clinical Oncology/American Society of Hematology clinical practice guideline update. J Clin Oncol 26 (2008) 132-149